| Literature DB >> 12966788 |
H Goldschmidt1, F W Cremer, T M Möhler, A D Ho.
Abstract
Multiple myeloma is one of the 20 most frequent malignancies in Germany. Initial symptoms are usually non-specific. Assessment of bone marrow and laboratory data as well as imaging techniques are essential for diagnosis and prognostic evaluation. Data from molecular cytogenetics have led to a better understanding of the pathogenesis of multiple myeloma. Cytostatic therapy with alcylating agents and glucocorticoids prolongs the survival. High-dose therapy followed by transplantation of autologous hematopoietic stem cells improves prognosis for patients up to the age of 70. Currently, modifications of allogeneic hematopoietic stem cell transplantation, anti-angiogeneic and immunomodulatory drugs as well as proteasome inhibitors are evaluated in clinical trials. Supportive care has derived benefit from the introduction of new bisphosphonates.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12966788 DOI: 10.1007/s00108-003-0920-x
Source DB: PubMed Journal: Internist (Berl) ISSN: 0020-9554 Impact factor: 0.743